

REMARKS

Claims 1-3 and 5-9 are amended. Claim 13, which is drawn to the elected species, is new. Claims 1 and 2 are amended to include sequence identifiers, as requested by the Examiner. Claims 1-3 and 5-8 are amended for clarity. Claims 7 and 9 are amended to include a period.

No new matter is added.

Parent Data

In the Office Action, the Examiner made note of similarities to the parent application 10/716,846. Applicants note that the specification of the present application includes experimental details and structures of several compounds (e.g., the elected species described below) not included in the parent application 10/716,846, now issued as U.S. Patent 7,265,093.

Claim Observations


In the Office Action, the Examiner made note of several issues with the claims. The Examiner's attention is drawn to the claims as filed, where the issues identified by the Examiner are rendered moot. The cited issues relate to a series of typographical errors in the listing of the claims in the preliminary amendment dated May 17, 2006. Applicants regret any inconvenience caused Examiner by these typographical errors. In the preliminary amendment, only claim 8 was amended to remove a minor issue of multiple dependency. The listing of the claims presented herein reflects the claims as originally filed, plus the amendment to claim 8 filed May 17, 2006.

Restriction Requirement

In the Office Action, the Examiner therein required election of one of the following groups of claims:

- Group I: Claims 1-8; and
- Group II: Claims 9-12.

The Applicants hereby elect to prosecute the claims of Group I, claims 1-8, drawn to a tTGase inhibitor, without traverse. The Applicants hereby elect to prosecute the following species:



{(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl}-carbamic acid pyridin-3-ylmethyl ester

The compound is listed at paragraph 116 of the published US Patent application, and corresponds to structure 3c in Table 1.

The Applicants expressly reserve the right under 35 USC §121 to file a divisional application directed to the non-elected subject matter or any subject matter disclosed in this application during the pendency of this application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number STAN-258US7.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: August 12, 2011

By: 

Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231